UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Hadi, M. [1 ]
Swinburn, P. [1 ]
de Freitas, H. M. [1 ]
Ito, T. [2 ]
机构：
[1] Mapi Grp, London, England
[2] Janssen Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.242
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM175
引用
收藏
页码：A389 / A389
页数：1
相关论文
共 50 条
  • [11] Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma
    Thompson, P. A.
    Prince, H. M.
    Seymour, J. F.
    Ritchie, D.
    Stokes, K.
    Burbury, K.
    Wolf, M.
    Peinert, S.
    Joyce, T.
    Harrison, S. J.
    BONE MARROW TRANSPLANTATION, 2011, 46 (05) : 764 - 765
  • [12] Bevacizumab in heavily pre-treated ovarian cancer patients and the predictive value of serum VEGF
    Smerdel, M.
    Steffensen, K. D.
    Waldstrom, M.
    Brandslund, I.
    Jakobsen, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 451 - 451
  • [13] Hematopoietic progenitor cell mobilization and transplantation is feasible even after autologous SCT in heavily pre-treated patients with multiple myeloma
    Guenther, A.
    Schub, N.
    Buwitt-Beckmann, U.
    Trost, B.
    Humpe, A.
    Gramatzki, M.
    ONKOLOGIE, 2013, 36 : 237 - 237
  • [14] A Real-World Study of Panobinostat, Weekly Bortezomib, and Dexamethasone in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients
    Bird, Sarah
    Pawlyn, Charlotte
    Nallamilli, Susanna
    Sriskandarajah, Priya
    Kaiser, Martin
    Yong, Kwee
    Popat, Rakesh
    Rabin, Neil
    Boyd, Kevin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S306 - S306
  • [15] PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRE-TREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE
    Cerchione, C.
    Martinelli, G.
    Nappi, D.
    Pareto, A. E.
    Lucchesi, A.
    Musuraca, G.
    Ronconi, S.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2019, 104 : 148 - 148
  • [16] Cyberknife SBRT for liver metastases in heavily pre-treated patients
    Martenka, P.
    Skrobala, A.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S563 - S563
  • [17] A 'real-world' study of panobinostat, bortezomib and dexamethasone in a very heavily pre-treated population of myeloma patients
    Bird, Sarah
    Sriskandarajah, Priya
    Kaiser, Martin
    Pawlyn, Charlotte
    Boyd, Kevin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E244 - E245
  • [18] Thalidomide in combination with idarubicin, dexamethasone and etoposide (TIDE) is an effective oral combination in heavily pre-treated myeloma patients
    Linch, Mark D.
    Jenner, Matthew W.
    Dines, Sharon
    Davies, Faith E.
    Morgan, Gareth J.
    BLOOD, 2007, 110 (11) : 285B - 285B
  • [19] Lenolidamide (Revlimid), in combination with cyclophosphamide and dexamethasone (CRD) is an effective regimen for heavily pre-treated myeloma patients.
    Morgan, Gareth J.
    Schey, Stephen
    Wu, Ping
    Srikanth, M.
    Phekoo, Karen J.
    Jenner, Matthew W.
    Dines, Sharon
    Saso, Radovan
    Davies, Faith E.
    BLOOD, 2006, 108 (11) : 1015A - 1015A
  • [20] Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents' Era
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S442 - S442
12345